Zimmer Biomet Holdings (ZBH) Stock Forecast & Price Target

Compare

1,035 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZBH Analyst Ratings

Hold

7 Buy

11 Hold

2 Sell

Based on 20 analysts giving stock ratings to

Zimmer

Biomet Holdings

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZBH Stock 12 Month Forecast

Average Price Target

$109.89

▲(6.95% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Zimmer Biomet Holdings in the last 3 months. The average price target is $109.89 with a high forecast of $138.00 and a low forecast of $96.00. The average price target represents a 6.95% change from the last price of $102.75.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"89":"$89","114":"$114","139":"$139","101.5":"$101.5","126.5":"$126.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":138,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$138.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":109.89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$109.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$96.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[89,101.5,114,126.5,139],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.62,94.26461538461538,97.90923076923077,101.55384615384615,105.19846153846154,108.84307692307692,112.48769230769231,116.13230769230769,119.77692307692308,123.42153846153846,127.06615384615384,130.71076923076924,134.35538461538462,{"y":138,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.62,92.10230769230769,93.58461538461539,95.06692307692308,96.54923076923077,98.03153846153846,99.51384615384616,100.99615384615385,102.47846153846154,103.96076923076923,105.44307692307693,106.92538461538462,108.40769230769232,{"y":109.89,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.62,91.03384615384616,91.44769230769231,91.86153846153846,92.27538461538462,92.68923076923078,93.10307692307693,93.51692307692308,93.93076923076923,94.34461538461538,94.75846153846155,95.1723076923077,95.58615384615385,{"y":96,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":110.1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.59,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.52,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.13,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.96,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.83,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.08,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.87,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$138.00

Average Price Target$109.89

Lowest Price Target$96.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lila Implantra

TR | OpenAI - 4o

$112→$116

Buy

12.90%

Upside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Patrick Wood

Morgan Stanley

$95→$100

Hold

-2.68%

Downside

Reiterated

08/11/25

Morgan Stanley Sticks to Its Hold Rating for Zimmer Biomet Holdings (ZBH)ZBH.N Zimmer Biomet Holdings Inc Equal-Weight; Price target revised from 95.00 to 100.00.

Richard Newitter

Truist Financial

―

Hold

―

Reiterated

08/08/25

Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (NYSE: ZBH) and Crinetics Pharmaceuticals (NASDAQ: CRNX)

Jayson Bedford

Raymond James

$104→$113

Buy

9.98%

Upside

Reiterated

08/08/25

Zimmer Biomet price target raised to $113 from $104 at Raymond JamesZimmer Biomet price target raised to $113 from $104 at Raymond James

Jeff Johnson

Robert W. Baird

$115→$125

Buy

21.65%

Upside

Reiterated

08/08/25

Zimmer Biomet price target raised to $125 from $115 at BairdZimmer Biomet price target raised to $125 from $115 at Baird

Robbie Marcus

J.P. Morgan

$105→$115

Buy

11.92%

Upside

Reiterated

08/08/25

Zimmer Biomet Holdings (ZBH) Receives a Buy from J.P. MorganJPMorgan analyst Robbie Marcus raised the price target on Zimmer Biomet (NYSE: ZBH) to $115.00 (from $105.00) while maintaining a Overweight rating.

Lee Hambright

Bernstein

$100→$105

Hold

2.19%

Upside

Reiterated

08/08/25

Bernstein Sticks to Their Hold Rating for Zimmer Biomet Holdings (ZBH)

Jason Wittes

Roth MKM

$135→$138

Buy

34.31%

Upside

Reiterated

08/08/25

Zimmer Biomet price target raised to $138 from $135 at Roth CapitalZimmer Biomet price target raised to $138 from $135 at Roth Capital

Danielle Antalffy

UBS

$91→$96

Sell

-6.57%

Downside

Reiterated

08/08/25

Zimmer Biomet price target raised to $96 from $91 at UBSZimmer Biomet price target raised to $96 from $91 at UBS

Matthew O'Brien

Piper Sandler

$100

Hold

-2.68%

Downside

Reiterated

08/08/25

Piper Sandler Keeps Their Hold Rating on Zimmer Biomet Holdings (ZBH)

Matthew Taylor

Jefferies

$103→$110

Hold

7.06%

Upside

Reiterated

08/07/25

Jefferies Remains a Hold on Zimmer Biomet Holdings (ZBH)

Travis Steed

Bank of America Securities

$110

Hold

7.06%

Upside

Reiterated

08/07/25

Cautious Outlook and Hold Recommendation for Zimmer Biomet Holdings Amid Volatility Concerns

Caitlin Cronin

Canaccord Genuity

$101

Hold

-1.70%

Downside

Reiterated

08/07/25

Canaccord Genuity Reaffirms Their Hold Rating on Zimmer Biomet Holdings (ZBH)

Josh Jennings

TD Cowen

$104

Hold

1.22%

Upside

Reiterated

08/07/25

Zimmer Biomet Holdings: Hold Rating Maintained Amid Stable Growth and Second-Half Optimism

Shagun Singh Chadha

RBC Capital

$112→$115

Buy

11.92%

Upside

Reiterated

08/07/25

Analysts Conflicted on These Healthcare Names: Sangamo Biosciences (NASDAQ: SGMO), Pliant Therapeutics (NASDAQ: PLRX) and Zimmer Biomet Holdings (NYSE: ZBH)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lila Implantra

TR | OpenAI - 4o

$112→$116

Buy

12.90%

Upside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Patrick Wood

Morgan Stanley

$95→$100

Hold

-2.68%

Downside

Reiterated

08/11/25

Morgan Stanley Sticks to Its Hold Rating for Zimmer Biomet Holdings (ZBH)ZBH.N Zimmer Biomet Holdings Inc Equal-Weight; Price target revised from 95.00 to 100.00.

Richard Newitter

Truist Financial

―

Hold

―

Reiterated

08/08/25

Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (NYSE: ZBH) and Crinetics Pharmaceuticals (NASDAQ: CRNX)

Jayson Bedford

Raymond James

$104→$113

Buy

9.98%

Upside

Reiterated

08/08/25

Zimmer Biomet price target raised to $113 from $104 at Raymond JamesZimmer Biomet price target raised to $113 from $104 at Raymond James

Jeff Johnson

Robert W. Baird

$115→$125

Buy

21.65%

Upside

Reiterated

08/08/25

Zimmer Biomet price target raised to $125 from $115 at BairdZimmer Biomet price target raised to $125 from $115 at Baird

Robbie Marcus

J.P. Morgan

$105→$115

Buy

11.92%

Upside

Reiterated

08/08/25

Lee Hambright

Bernstein

$100→$105

Hold

2.19%

Upside

Reiterated

08/08/25

Bernstein Sticks to Their Hold Rating for Zimmer Biomet Holdings (ZBH)

Jason Wittes

Roth MKM

$135→$138

Buy

34.31%

Upside

Reiterated

08/08/25

Zimmer Biomet price target raised to $138 from $135 at Roth CapitalZimmer Biomet price target raised to $138 from $135 at Roth Capital

Danielle Antalffy

UBS

$91→$96

Sell

-6.57%

Downside

Reiterated

08/08/25

Zimmer Biomet price target raised to $96 from $91 at UBSZimmer Biomet price target raised to $96 from $91 at UBS

Matthew O'Brien

Piper Sandler

$100

Hold

-2.68%

Downside

Reiterated

08/08/25

Piper Sandler Keeps Their Hold Rating on Zimmer Biomet Holdings (ZBH)

Matthew Taylor

Jefferies

$103→$110

Hold

7.06%

Upside

Reiterated

08/07/25

Jefferies Remains a Hold on Zimmer Biomet Holdings (ZBH)

Travis Steed

Bank of America Securities

$110

Hold

7.06%

Upside

Reiterated

08/07/25

Cautious Outlook and Hold Recommendation for Zimmer Biomet Holdings Amid Volatility Concerns

Caitlin Cronin

Canaccord Genuity

$101

Hold

-1.70%

Downside

Reiterated

08/07/25

Canaccord Genuity Reaffirms Their Hold Rating on Zimmer Biomet Holdings (ZBH)

Josh Jennings

TD Cowen

$104

Hold

1.22%

Upside

Reiterated

08/07/25

Zimmer Biomet Holdings: Hold Rating Maintained Amid Stable Growth and Second-Half Optimism

Shagun Singh Chadha

RBC Capital

$112→$115

Buy

11.92%

Upside

Reiterated

08/07/25

Analysts Conflicted on These Healthcare Names: Sangamo Biosciences (NASDAQ: SGMO), Pliant Therapeutics (NASDAQ: PLRX) and Zimmer Biomet Holdings (NYSE: ZBH)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zimmer Biomet Holdings

1 Month

xxx

Success Rate

13/22 ratings generated profit

Average Return

+0.63%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 59.09% of your transactions generating a profit, with an average return of +0.63% per trade.

3 Months

xxx

Success Rate

27/45 ratings generated profit

Average Return

+2.37%

assigned a xxx

rating 10 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +2.37% per trade.

1 Year

Steven LichtmanOppenheimer

Success Rate

29/45 ratings generated profit

Average Return

+5.21%

assigned a buy rating 10 months ago

Copying Steven Lichtman's trades and holding each position for 1 Year would result in 64.44% of your transactions generating a profit, with an average return of +5.21% per trade.

2 Years

xxx

Success Rate

25/45 ratings generated profit

Average Return

+5.68%

assigned a xxx

rating 10 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of +5.68% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZBH Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZBH has received 16 Buy Ratings, 21 Hold Ratings, and 2 Sell Ratings. ZBH average Analyst price target in the past 3 months is 109.89.

Each month's total comprises the sum of three months' worth of ratings.

ZBH Financial Forecast

ZBH Earnings Forecast

Next quarter’s earnings estimate for ZBH is $1.88 with a range of $1.78 to $2.03. The previous quarter’s EPS was $2.07. ZBH beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.26% of the time in the same period. In the last calendar year ZBH has Outperformed its overall industry.

ZBH Sales Forecast

Next quarter’s sales forecast for ZBH is $2.01B with a range of $1.99B to $2.03B. The previous quarter’s sales results were $2.08B. ZBH beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.42% of the time in the same period. In the last calendar year ZBH has Outperformed its overall industry.

ZBH Stock Forecast FAQ

What is ZBH’s average 12-month price target, according to analysts?

Based on analyst ratings, Zimmer Biomet Holdings’s 12-month average price target is 109.89.

What is ZBH’s upside potential, based on the analysts’ average price target?

Zimmer Biomet Holdings has 6.95% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ZBH a Buy, Sell or Hold?

Zimmer Biomet Holdings has a consensus rating of Hold which is based on 7 buy ratings, 11 hold ratings and 2 sell ratings.

What is Zimmer Biomet Holdings’s price target?

The average price target for Zimmer Biomet Holdings is 109.89. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $138.00 ,the lowest forecast is $96.00. The average price target represents 6.95% Increase from the current price of $102.75.

What do analysts say about Zimmer Biomet Holdings?

Zimmer Biomet Holdings’s analyst rating consensus is a Hold. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of ZBH?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Zimmer Biomet Holdings (ZBH) Stock Forecast & Price Target

ZBH Analyst Ratings

ZBH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zimmer Biomet Holdings

ZBH Analyst Recommendation Trends

ZBH Financial Forecast

ZBH Earnings Forecast

ZBH Sales Forecast

ZBH Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts